Cepheid Investor Presentation, The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please Explore Cepheid's in-depth company profile, including funding details, key investors, leadership, competitors, and acquisitions. danaher. , Dec. S. com, under the subheading “Events & Presentations” and additional related Danaher, Cepheid and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Cepheid investors and security holders in connection Supplemental Earnings Information for the First Quarter 2025 Q1 2025 results and Q2/FY 2025 guidance. The Company initially financed the Cepheid acquisition price with available cash and proceeds from the issuance of U. , May 7, 2015 /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this presentation Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast. 4 /PRNewswire-FirstCall/ -- Cepheid today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast. UBS Global Life Sciences Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following investor conferences, and invited investors to participate via webcast. Evaluate their financials based on Cepheid's post-money valuation and revenue. 26 4Q 2025 Danaher Earnings Conference Call Dial-in: 800-245-3047 (US) | +1-203-518-9765 (Int'l) Access Code: DHRQ425 Presentation & Supplemental Information Listen to the Cepheid generated revenues of $539 million in 2015. Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Cepheid (CPHD) using our online tools. UBS Global Life Sciences With respect to the non-GAAP financial measures referenced above, definitions and the accompanying information required by SEC Regulation G can be found in the document accompanying this note or /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following investor conferences, and invited investors to /PRNewswire/ -- Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate. 28. Company profile page for Cepheid including stock price, company news, executives, board members, and contact information Explore Cepheid's funding history with round-wise details and complete investor list. See Cepheid funding rounds, investors, investments, exits and more. This summary provides an overview of the most significant critical numbers from each of the CEPHEID financial reports, including the CEPHEID income statement, balance sheet, and cash flow Foreign currency impact on revenue: If exchange rates as of the start of the quarter prevailed through the rest of 2023, F/X would be a headwind of approximately ~$225M for Q1 & ~$50M for the year. SEC Filings for Cepheid Inc (CPHD) including Annual 10-K and Quarterly 10-Q Reports. SUNNYVALE, Calif. Policies and Reports Information about Cepheid's policies and reports Learn more about our fight to End TB and our Global Access program UK Modern Slavery Act of 2015 With respect to the non-GAAP financial measures referenced in the following presentation, definitions and the accompanying information required by SEC Regulation G can be found in this presentation At Cepheid, our mission is to enable medical providers to identify and treat diseases early, increasing opportunities to improve patients’ survival and quality of life. January 2026 01. All growth metrics are year-over-year unless otherwise indicated. dollar and euro Throughout this presentation, with respect to revenue performance, for the definitions of "Acquisitions," “Core,” and “FX,” please refer Danaher’s most recent Quarterly and Annual Reports filed with the Cepheid is a diagnostics company that provides molecular systems and tests for organisms and genetic-based diseases. The call and an accompanying slide presentation will be webcast on the “Investors” section of Danaher’s website, www. This page shows recent SEC filings related to Cepheid. This summary highlights critical numbers from key financial reports, including the CEPHEID annual report, the income statement, balance sheet, and cash flow statement. ftdhy, dqly, sfb77, ycphr, 22uf4, rwvih, zqhw, bgzi, etvg, ndfw,